Cerebral metabolism during vegetative state and after recovery to consciousness

One way to approach the study of consciousness is to explore lesional cases in which impairment of consciousness is the prominent clinical sign. Vegetative state is such a condition wherein awareness is abolished whereas arousal persists. It can be diagnosed clinically soon after a brain injury and may be reversible (as in the following case report) or progress to a persistent vegetative state or death. The distinction between vegetative state and persistent vegetative state is that the second is defined as a vegetative state that has continued or endured for at least 1 month. We present a patient who developed a vegetative state after carbon monoxide poisoning and in whom we had the opportunity to measure brain glucose metabolism distribution during the vegetative state and after recovery to consciousness. Using [18F]fluoro-deoxyglucose (FDG) PET and statistical parametric mapping (SPM) we compared both patient’s sets to a normal control population. Our findings offer an insight into the neural correlates of “awareness”, pointing to a critical role for posterior associative cortices in consciousness.

A 40 year old right handed woman attempted suicide through CO intoxication and was found unconscious. She was treated with hyperbaric oxygen but evolved to a vegetative state diagnosed according to the following criteria: (1) spontaneous eye opening without evidence of awareness of the environment; (2) no evidence of reproducible voluntary behavioural responses to any stimuli; (3) no evidence of language comprehension or expression; (4) intermittent wakefulness and behaviourally assessed sleep-wake cycles; (5) normal cardiorespiratory function and blood pressure control; (6) preserved pupillary, oculocephalic, corneal, and vestibulo-ocular reflexes. Brain MRI performed 14 days after admission was normal. Electroencephalography showed a 6 Hz basal activity with more pronounced slowing on the left parietal regions. Auditory evoked potentials were normal. Somaesthetic evoked potentials of the median nerve showed normal latency and amplitude of P14 and N20 potentials without any late cortical components. After remaining in a vegetative state for 19 days the patient regained consciousness. Her sequence consisted of a bilateral spastic paresis of upper and lower limbs. Neuropsychological testing 1 month after admission showed an attention deficit with moderate impairment of short term memory. One year after the accident she showed a spastic gait with altered fine motor function, most prominent on the right, a slurred speech, and minor short term memory disturbances. FDG-PET was performed during the vegetative state (day 15 after admission) and after recovery to consciousness (day 57).

The control population consisted of 48 drug free, healthy volunteers, aged from 18 to 76 years (mean: 42 (SD 21) years). The study was approved by the ethics committee of the University of Liège. Informed consent was obtained by the husband of the patient and for all control subjects. Five to 10 mCi FDG was injected intravenously; PET data were obtained on a Siemens CTI 951 R 16/31 scanner in bidimensional mode. Arterial blood samples were drawn during the whole procedure and cerebral metabolic glucose rates (CMRGlu) were calculated for all subjects. PET data were analysed using SPM software (SPM96 version; Welcome Department of Cognitive Neurology, Institute of Neurology, London, UK). The use of SPM to assess between subject (rather than within subject) variability is unlikely to alter the relevance of our results given their high degree of significance. Data from each subject were normalised to a standard stereotactic space and then smoothed with a 16 mm full width half maximum isotropic kernel. The analysis identified brain regions where glucose metabolism was significantly lower in each patient scan compared with the control group. The resulting foci were characterised in terms of peak height over the entire volume analysed at a threshold of corrected p<0.05.

During the vegetative state, average grey matter glucose metabolism was 38% lower than in controls (4.5 ± 7.3 (SD 1.4) mg/100 g/min). No substantial change in mean CMRGlu was found after recovery (4.7 ± 100 g/min). During the vegetative state, significant regional CMRGlu decreases were found in the left and right superior parietal lobule; the left inferior parietal lobule; the precuneus; the left superior occipital, superior and middle temporal gyri; and the premotor and postcentral and precentral cortex (figure, yellow colour). After recovery, metabolic impairment was confined to the left and right precentral and postcentral gyri and premotor cortices (figure, blue colour).

This case report offers an insight into the neural correlates of human consciousness (at least, external awareness as it can be assessed at the patient’s bedside). Given that global glucose utilisation levels remained essentially the same, the recovery of consciousness seems related to a modification of the regional distribution of brain function rather than to the global resumption of cerebral metabolism. The main decreases in metabolism seen during the vegetative state but not after recovery were found in parietal areas, including the precuneus. This is in agreement with postmortem findings in persistent vegetative state, in which involvement of the association cortices is reported as a critical neuroanatomical substrate and with PET studies in postanoxic syndrome, in which the parieto-occipital cortex showed the most consistent impairment. The functions of these areas are manifold: lateral parietal areas are involved in spatial perception and attention, working memory, mental imagery, and language, whereas the precuneus is activated in episodic memory retrieval, modulation of visual perception by mental imagery, and attention. Our data point to a critical role for these posterior associative cortices in the emergence of conscious experience.

STEVEN LAUREYS
CHRISTIAN LEMAIRE
PIERRE MAUQUE
Cyclotron Research Centre, University of Liège, Sart Tilman, 4000 Liège, Belgium

CHRISTOPHE PHILLIPS
Institute of Cognitive Neurology, University College London, Alexandra House, 1 Queen Square, London WC1N3AR, England, UK

GEORGE FRANCK
Department of Neurology, CHU Liège Sart, Tilmann B-35, 4000 Liège, Belgium

Correspondence to: Dr Pierre Maquet, Cyclotron Research Centre (B30), University of Liège, Sart Tilman, 4000 Liège, Belgium Telephone 0032 43 66 36 87; fax 0032 43 66 29 46; email maquet@pet.crc.ac.be

Electrical inexcitability of nerves and muscles in severe infantile spinal muscular atrophy

Spinal muscular atrophy (SMA) is one of the most common fatal autosomal recessive disorders, characterised by progressive degeneration of anterior horn cells. Before the advent of genetic testing, the diagnosis of SMA was based on clinical, histopathological, and electrophysiological features. In 1992, the International SMA Consortium defined diagnostic criteria of proximal SMA based on clinical findings. In SMA type I (severe; Werdnig-Hoffmann disease), affected persons have onset of symptoms before 6 months of age and are never able to sit without support. Electromyography demonstrates denervation features. In early 1995, the candidate gene, the survival motor neuron (SMN) gene, was identified, making the confirmation of SMA by DNA analysis possible.

With the availability of a genetic test for SMA, many investigators are refining the diagnostic criteria published by the Consortium. Studies involving hundreds of patients worldwide have disclosed a subset of patients who fulfil at least one exclusion criterion defined by the Consortium. We identified an infant with severe SMA who fulfilled two exclusion criteria and also showed inexcitable nerves as well as muscles. This report will further delineate the wide range of phenotypes for this particular gene mutation.

A 2945-g male infant was born at term. Fetal movements were noted at 13 weeks of gestation. Chorionic villus sampling at 10 weeks of gestation disclosed normal chromosomal decreases. Decreased fetal movement and polyhydramnios were noted about 34 weeks of gestation. At delivery, the infant was cyanotic with no respiratory effort and was subsequently intubated. On physical examination, the infant had no spontaneous movements. He opened his eyes with brief fixation but no following. Tongue fasciculations were present. Other cranial nerves seemed intact. Mild flexion contractures of both elbows, knees, and ankles were noted. Tone was flaccid in the upper limbs and lower limbs, and there was no movement response to painful stimu- lus. Deep tendon reflexes were absent. Brain MRI disclosed mild diffuse cortical atrophy. His EMG was severely abnormal, with widespread fibrillations and absent voluntary motor units except in the genioglossus, where mildly neuronegenic motor units with decreased recruitment were seen. Stimulation of the median, ulnar, tibial, and peroneal nerves with a maximal stimulus resulted in no clinical or electrical response. The biceps brachii and rectus femoris muscles were electrically inexcitable by direct needle stimulation. Median, ulnar, and sural sensory potentials were not obtainable. DNA testing showed a homozygous deletion of exons 7 and 8 of the telomeric SMN gene, all three siblings showed a large deletion in the region that includes all alleles of the multi-copy markers Ag1-CA and C212, localised at the 5' end of the two SMN gene copies. It has been postulated that the severity of disease may be correlated to the extent of a deletion involving the SMN gene and the multicyclop markers. The infant in our report with SMA type I showed electrical inexcitability of motor nerves as well as the characteristic alteration of the SMN gene.

Although it has been shown for some time from histological studies that sensory systems are involved in SMA, electrophysiological sensory findings have been previously reported only once. Sensory nerve conduction velocity was tested in an index with severe SMA and showed no recordable potential, but the infant in our report also exhibited universal absence of sensory potentials. In both cases, DNA analysis disclosed the 5q deletion. It is unclear whether this finding represents a distinct entity or merely the severe end of classic Werdnig-Hoffmann disease. The diagnostic criteria produced by the International SMA Consortium currently lists “absence of abnormal sensory action potentials” as an exclusion criterion. Our finding of absent sensory potentials in a 5q deletion established case of SMA indicates further need for revision of the Consortium criteria. Studies involving large numbers of patients with SMA have identified cases of SMA variants. These patients were diagnosed as infantile SMA by the presence of proximal weakness and atrophy, hypotonia, and evidence of neuromuscular alterations in EMG and muscle biopsy. In addition, these patients also exhibited one of the exclusion criteria defined by the Consortium—for example, diaphragmatic weakness, involvement of the CNS, or arthrogryposis. Although these patients did not show the typical SMN deletion and were therefore probably not linked to chromosome 5q, they could have had point mutations. The infant in our report showed no respiratory effort after birth, indicating diaphragmatic weakness. He did, however, possess the charac- teristic SMN gene alterations. This finding suggests that diaphragmatic weakness should be reconsidered as an exclusion criterion by the Consortium.

Review of the literature disclosed no previous reports of electrophysiologically inexcitable muscles in SMA. This phenomenon is known to occur in a few other neuromuscular conditions such as periodic paralysis and critical illness polyneuropathy. Fibrillations, as seen in the infant in our report, are commonly seen in acute denervation and are thought to be caused by perturbation of the sarcolemmal membrane, rendering it unstable. One possi- bility may be that acute severe denervation in SMA type I can result in abnormal function of the membrane to make it electrically inex- citable. Further electrophysiological studies at the cellular level are required to delineate this interesting finding.

A. C. Kuo
Department of Pediatrics
Stefan-M Pulst
Dawn S Eilashiv
Cameron R Adams
Division of Neurophysiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
Correspondence to: Dr Cameron R Adams, Department of Neurophysiology, Cedars-Sinai Medical Center, 8631 West Third Street, Room 1145, East Tower, Los Angeles, CA 90048, USA.
phy. Blood was taken for the measurement of levodopa and metabolites 2.5 hours after ingestion, and again after 9, 14.5, 34, and 132.5 hours. Using high performance liquid chromatography with electrochemical detection, we measured the plasma concentrations of levodopa, 3-o-methyldopa, dihydroxyphenylacetic acid, homovanillic acid, noradrenaline, adrenaline, and dopamine. The time course of these concentrations of levodopa and 3-o-methyldopa are shown in the figure. After 24 hours the patient was moved from the intensive care unit to a normal medical ward. At this point no neuropsychiatric signs of levodopa intoxication could be detected. Clinically, the most prominent symptoms of levodopa overdose are confusion, agitation, sleeplessness, and excessive motor activity. The initial levodopa concentration in our patient was 66763 ng/ml, the concentrations of DOPAC, homovanillic acid, noradrenaline, adrenaline, and dopamine were raised 2.5 hours after ingestion and rapidly returned to normal. A very noticeable feature of this case was the maximal bilateral mydriasis, with absent light reaction, at the time of the maximal intoxication with a 30-fold increase in plasma levodopa concentration. To our knowledge, it is the first report of a levodopa intoxication with maximally dilated, light plasma levodopa concentration. To our knowledge, the relationship between ambulant ingestion and plasma concentration seems to be linear, at least in this dose range.

We conclude from these findings that in cases of suspected levodopa intoxication, some hours previously, it could be important to measure the concentration of 3-o-methyldopa, so as not to overlook an overdose with levodopa, which may be due to a suicide attempt. In addition to the diagnostic uncertainty in relation to the immediate treatment of the patient, this would also have an effect on further psychiatric and psychological therapy.

H J STUERENBURG
EG H SCHÖSER
Neurological Department, University Hospital Hamburg-Eppendorf, Hamburg, Germany

Correspondence to: Dr Hans Joerg Stuermen, Neurological Department, University-Hospital-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. Telephone 0049 40 4717 4832; fax 0049 40 4717 5086; email stuerenburg@uke.uni-hamburg.de


The use of olanzapine for movement disorder in Huntington's disease: a first case report

Movement disorder is a prominent feature of Huntington's disease and consists of involuntary and voluntary components as well as associated bradykinesia. Pharmacological treatment is problematic because of the side effects of the drugs used, which may further compromise cognitive functioning and mobility. Patients are often not subjectively aware of their movements but can be considerably disabled by them and carers are often distressed and enquire about treatment options. If drug treatment is considered it is important to achieve the maximum improvement in movements with the minimum of negative side effects. This paper describes the effect of olanzapine on movements when other treatment options had been ineffective or limited by side effects.

Huntington's disease is a hereditary, progressive neurodegenerative disorder. It consists of a triad of symptoms comprising motor, psychological, and cognitive abnormalities. The motor component consists of involuntary choreiform movements and increasing difficulties with voluntary movement. The degree of the involuntary movements is variable but in some patients can be very marked. Progression over time of the movement disorder in Huntington's disease can be monitored using the quantitative neurological examination (QNE). This measure has three subscales, an eye movement scale, a motor impairment scale (MIS) quantifying voluntary movement, and a chorea scale measuring involuntar movement.

Pharmacological control of the symptoms has been shown to be effective with dopamine antagonists, but their use is limited because of the side effects. Clinically, the most problematic of these are sedation, cognitive slowing, increased mobility problems, and hypotension. The inability of traditional dopamine antagonists to improve functional capacity, despite ameliorating the chorea, may possibly be due to suppression of voluntary motor activity. Tardive dyskinesia has occasionally been reported in patients with Huntington's disease treated with these drugs. The atypical antipsychotic clozapine has been shown to be effective in improving the movement disorder. However, in a double blind randomised trial of clozapine which included patients who were already receiving traditional antipsychotic medication, a group who had not received drug treatments for their movement disorder, chorea was reduced in those who were antipsychotic naive only and the authors concluded that clozapine was of little additional effect in Huntington's disease. Olanzapine is a new atypical antipsychotic drug. It is a thienobenzodiazepine structurally very similar to clozapine. Unlike clozapine it is not associated with the potentially serious side effect of agranulocytosis and therefore frequent blood monitoring is not necessary.

This report describes the progress of a man who has Huntington's disease. He developed a marked movement disorder and was unable to tolerate both sulpiride and risperidone but had symptomatic improvement when treated with olanzapine.

He is a man in his early 50s who had a confirmatory genetic test for Huntington's disease in 1994, after the development of clinically obvious motor symptoms. It is likely that the onset of symptoms had occurred a few years previously as he had experienced difficulties in concentration and coordination of his work, attributed at the time to stress, leading to the loss of employment. In addition his family, watching family videos of a few years earlier, thought that there were early signs of his movement disorder. However there was no known family history of Huntington's disease which might have led to an earlier diagnosis. By May 1995 his involuntary movements were becoming more noticeable, although control of voluntary movement was good. A trial of sulpiride commencing at 200 mg twice daily and increasing over 1 week to 800 mg daily was undertaken with a subsequent decrease in the frequency and extent of involuntary movement recorded in case notes; unfortunately the QNE was not repeated at this time. However, the patient experienced a subjective slowing of his cognitive processes, concurrently became depressed, and decided to stop the treatment within 3 weeks. Paroxetine, a selective serotonin reuptake inhibitor antidepressant, was started at a dose of 20 mg a day, which led to an improvement in his low mood. His involuntary movements continued to cause difficulties in his daily living. He was unable to sit comfortably in a chair and when out he found that he was knocking into them. He agreed to a trial of...
risperidone. This was started at a dose of 1mg twice daily, increasing to a dose of 1mg four times a day over a period of 2 weeks, stopped after a brief period. He developed hypertension (blood pressure 100/60 mg Hg), complaining of dizziness after the initial dose. His blood pressure remained stable, although low, after this and as there was improvement in his movements the drug was continued. However, he decided to stop the risperidone after 4 months because of his subjective experience of slowed thinking and occasional dizziness. A repeated trial of sulpiride was carried out in March 1997. Sulpiride was started at a dose of 200 mg twice a day and increased to a total daily dose of 1000 mg over 2 weeks. He was on sulpiride for 4 weeks with no improvement in his movements, so it was discontinued. The patient continued to experience low mood and after the discontinuation of sulpiride, his antidepresant drug was changed to lofepramine commencing at 70 mg once a day and increasing after a few days to 140 mg daily. There were no changes noted in his movements during this change. Although the patient was subjectively unaware of the extent of his movements his eyes were kept open. The experience of slowed thinking and occasional dizziness. A repeated trial of sulpiride was carried out in March 1997. Sulpiride was started at a dose of 200 mg twice a day and increased to a total daily dose of 1000 mg over 2 weeks. He was on sulpiride for 4 weeks with no improvement in his movements, so it was discontinued. The patient continued to experience low mood and after the discontinuation of sulpiride, his antidepresant drug was changed to lofepramine commencing at 70 mg once a day and increasing after a few days to 140 mg daily. There were no changes noted in his movements during this change.

In the absence of a cure for Huntington’s disease, it is very important that any intervention considered enhances the quality of life of the patient and improve overall functioning. It may not always be in the best interests of the patient to use drug treatments for the movement disorder. In those patients who have severe movements, however, a trial of treatment may be appropriate and continued if a clear benefit has been achieved. Neurological monitoring and the patient’s own perception of the effect of the drug must be taken into account.

The mechanism by which olanzapine may have beneficial effects is unclear. Olanzapine has been shown to have high affinity for a large number of receptors including D1, D2, D4, 5HT2A, 5HT2C, 5 HT3, α-1-adrenergic, histamine H1, and 5 muscarinic receptors. This binding profile is similar to clozapine, another atypical antipsychotic drug, but substantially different to the conventional antipsychotic haloperidol. Preferential loss of D2 projection neurons which are involved in a feedback loop normaly active in the suppression of involuntary movements is thought to be the pathophysiological basis of chorea in patients with Huntington’s disease. The D2 antagonist properties of olanzapine may explain its possible benefits in the improvement of chorea. However, the effect at other receptors such as D4 may also be important, as D4 receptor density has been shown to be raised in Huntington’s disease, therefore the D4/D2 ratio of activity may also be relevant. Differences in binding profile across a range of receptors may explain clinical differences in outcome when comparing different antipsychotic drugs.

This case report indicates that olanzapine may be a useful addition to the treatments for movement disorder, for some patients, and controlled trials of its use in Huntington’s disease would be welcome.

**Patient characteristics**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age at surgery</th>
<th>Sex</th>
<th>PD Years</th>
<th>H and Y* On/off</th>
<th>UPDRS off/parkinsonian/potent parkinsonism</th>
<th>Pallidotomy side</th>
<th>Transient side effects</th>
<th>Medication additional to levodopa</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>66</td>
<td>M</td>
<td>8</td>
<td>2/5</td>
<td>57/NP†</td>
<td>R</td>
<td>Slight facial paresis, swallowing problems, drooling</td>
<td>Trypriot, remazepam, alprazolam, apomorphine</td>
</tr>
<tr>
<td>2</td>
<td>43</td>
<td>F</td>
<td>7</td>
<td>2/2.5</td>
<td>2/2†</td>
<td>L</td>
<td>Slight dysarthria</td>
<td>Trihexifenidyl</td>
</tr>
<tr>
<td>3</td>
<td>48</td>
<td>M</td>
<td>15</td>
<td>2/3</td>
<td>55/L</td>
<td>L</td>
<td>Facial paresis</td>
<td>Pergolide, amantadine</td>
</tr>
<tr>
<td>4</td>
<td>50</td>
<td>M</td>
<td>12</td>
<td>2/2</td>
<td>45/22</td>
<td>L</td>
<td>Slight dysarthria</td>
<td>Selengeline, biperiden</td>
</tr>
<tr>
<td>5</td>
<td>53</td>
<td>M</td>
<td>14</td>
<td>2.5/4</td>
<td>69/36</td>
<td>R</td>
<td>Facial paresis, hypophonia</td>
<td>Pergolide, selegeline</td>
</tr>
<tr>
<td>6</td>
<td>58</td>
<td>M</td>
<td>13</td>
<td>2.5/3</td>
<td>48/27</td>
<td>L</td>
<td>Facial paresis, aphaia</td>
<td>Selengeline, biperiden</td>
</tr>
<tr>
<td>7</td>
<td>61</td>
<td>F</td>
<td>15</td>
<td>2.5/4</td>
<td>55/NP†</td>
<td>R</td>
<td>Slight paresis</td>
<td>Clozapine, temazepam, caspide</td>
</tr>
</tbody>
</table>

*H and Y=Hoehn and Yahr; †UPDRS off= unified Parkinson’s disease rating scale part 3 (motor examination), in a standardised off state, 12 hours without antiparkinson medication; SNMP=not performed.

**Quantitative neurological examination scores showing the progress of the movement disorder. 06/95: before trial sulpiride, no medication; 05/96: before risperidone, 20 mg paroxetine daily; 07/96: 1 mg risperidone four times daily and 20 mg paroxetine daily; 03/97: before retrial sulpiride, 20 mg paroxetine daily; 04/97: 400 mg sulpiride in the morning and 2 mg at night; 06/97: before olanzapine, 140 mg lofepramine daily; 06/97: 5 mg olanzapine at night, 140 mg lofepramine daily.**

**Letters, Correspondence, Book reviews, Correction**

**HEATHER C DIPPLE**
Department of Psychiatry, Leicester Royal Medical Health Service Trust, Huntington’s Disease Service, Mill Lodge, Mill Lane, Kegworth, Derby DE74 2EF, UK. Telephone 0044 1509 670774.


**Transient hiccups after posteroventral pallidotomy for Parkinson’s disease**

Hiccup is defined as an abrupt intermittent, involuntary, contraction of the diaphragmatic and external (inspiratory) intercostal muscles, with inhibition of expiratory intercostal activity. This results in a sudden inspiration, abruptly opposed by closure of the glottis. This results in a sudden inspiration, abruptly opposed by closure of the glottis.

Hiccups may result from various structural or functional disorders of the medulla, the efferent or effenter nerves to the respiratory muscles, and the gastrointestinal tract. Newson Davis performed a study of hiccup with electrophysiological techniques and concluded that hiccup is served by a supraspinal mechanism distinct from that generating rhythmic breathing. The principal site of interaction of the hiccup discharge with other descending drives to the respiratory motoneuron is at the spinal level. Neurogenic hiccup is particularly associated with structural lesions of the medulla oblongata.

Since 1994 we have performed 66 pallidotomies for Parkinson’s disease in 60 patients. So far, we have seen transient hiccups in seven patients after the operation (table). Our target coordinates for the posterior globus pallidus at the border of the medial and lateral segments are 2–3 mm anterior to the midcomissural point, 5 mm below the intercomissural line, and 22 mm lateral to the midline of the third ventricle. Ventriculography was performed for target
localisation. Patients started with a short schedule of corticosteroids (5 days) the night before surgery.

The hiccups started immediately after the operation or the next day, were intermittent, and the bouts of hiccup of six patients, with a duration of hours, resolved within 3 days after the procedure. One patient complained of yawning more often and frequent bouts of hiccup for 6 months.

Five patients were men. All patients were right handed. The mean age at surgery was 54 years and the mean duration of Parkinson’s disease was 12 years. All patients were taking levodopa. In four patients the hiccups appeared after a left sided pallidotomy. Patient 2 had a right sided thalamotomy 4 years before the pallidotomy. Patient 5 underwent a left sided pallidotomy 10 months before the right sided pallidotomy which caused the hiccups. The pallidotomies improved parkinsonism in the “off” state (table), contralateral dyskinesias, and pain accompanying Parkinson’s disease. Six patients had transient adverse events: four patients had a transient facial paresis postoperatively and two a slight transient dysarthria (table). Two patients had choreatic movements after the pallidotomy at the contralateral side which resolved spontaneously within 2 hours and is associated with a favourable surgical outcome. Postoperative MR scans were obtained in the first six patients, and showed that in five patients the lesions were located in the posterior part of the globus pallidus pars externa (GPe) and interna (figure). In patient 5 the lesion was situated slightly more anterior in the GPe and putamen. In patient 3 there was a small separate lesion more dorsal, probably an infarct.

We never encountered hiccups in 150 other stereotactic procedures for Parkinson’s disease, such as thalamotomies or deep brain stimulation electrode implantation in the thalamus and therefore it is unlikely that medication or positive contrast medium ven- triculography with Iohexol evoked the hiccup for 6 months. One patient complained of yawning more often and frequent bouts of hiccup for 6 months.

Psychological adjustment and self reported coping in stroke survivors with and without emotionalism

Emotionalism after stroke is common, occurring in 10%–20% of a community sample. Psychological factors in its cause or maintenance have not been studied; research has tended to concentrate instead on location of the stroke lesion. We suspect that one reason for this neglect of psychological aspects of emotionalism is that most people do not make a distinction between emotionalism, and pathological crying and laughing. As a result all disorders of emotionalism after stroke are stereotyped as being related to brain damage and therefore psychologically meaningless.

None the less, many patients with emotionalism describe their crying as provoked by emotionally congruent experiences, which makes the tearfulness seem understandable. In two previous studies we have shown that stroke patients with emotionalism have more symptoms of psychological disorder than do patients without emotionalism. In the present study, we explored further the psychological characteristics of stroke patients with emotionalism. Our aim was to determine whether they differed from patients without emotionalism in their psychological reactions to stroke, or in the coping strategies they reported.

Post-traumatic stress disorder is also characterised by recurrent episodes of intrusive and uncontrollable emotion, and we were therefore interested in whether patients with emotionalism also experienced the intrusive thoughts typical of post-traumatic stress disorder. Because emotionalism is often described as uncontrollable, we were interested in the possibility that patients were more generally helpless or avoidant in their responses to stroke. Again, because of the reported uncontrollability of emotionalism, we postulated that patients with emotionalism would report a more external locus of control than those without emotionalism.

Participants were adults admitted to local general hospitals after stroke, and were interviewed within 1 month of admission. Exclusions were due to poor physical health, cognitive impairment, communication difficulties, or lack of consent. Approval for the study was obtained from the local research ethics committees.

All participants completed a standardised measure of distress—the general health questionnaire, GHQ-12; a widely used measure of intrusive thoughts of the sort encountered in post-traumatic stress disorder—the impact of events rating scale; a measure of cognitive coping—the mental adjustment to stroke scale (O’Rourke S, Dennis M, MacHale S, Slattery J. The development of the mental adjustment to stroke scale: reliability, patient outcome and associations with mood and social activity, manuscript in preparation); and a measure of beliefs about responsibility for recovery from illness—the recovery locus of control scale. All the measures are self report questionnaires.

A total of 177 stroke patients were screened, of whom 112 were excluded. The 65 participants (29 men, 36 women) had a mean age of 71.8 years (range 43 to 88 years). Nineteen (29.2%) patients met our criterion for emotionalism, a rate similar to that found in other studies. Their scores on the study measures are compared with the scores of patients without emotionalism in the table. It might be that these associations with emotionalism were accounted for by the greater general levels of distress experienced by those with emotionalism. We therefore undertook analysis of covariance with GHQ-12 and presence of emotionalism as the covariates, and each of the other test items in turn as the independent variable. The results showed an association, after adjustment for GHQ-12 score, between emotionalism and the impact of events subscales intrusion.

Five months after left sided pallidotomy, MRI of patient 6. (A) transversal slice at the level of the anterior commissure and (B) 6 mm more ventral.
Comparison of stroke survivors with and without emotionalism, assessed in hospital 1 month after stroke

GHQ-12*
Recovery locus of control scale
Impact of events scale intrusion subscale**
Impact of events scale avoidance subscale* 
MASS Fighting subscale
MASS Anxious preoccupation subscale**
MASS Fatalism subscale* 
MASS Avoidance subscale
MASS Helplessness/hopelessness subscale**

MASS = Mental adjustment to stroke scale.
*p<0.05; **p<0.01, t-tests.

Mean (SD) of GHQ-12 score for emotionalism and non-emotionalism: (n=45) Mean (SD)
- Emotionalism = 3.2 (2.4) < 3.5 (3.5)
- Non-emotionalism = 3.3 (3.3) < 3.4 (3.7)

 Mean (SD) of Impact of events scale intrusion subscale: (n=11)
- Emotionalism = 2.9 (4.6) < 9.2 (6.6)
- Non-emotionalism = 4.7 (4.5) < 9.9 (6.1)

Mean (SD) of MASS Fighting subscale: (n=11), emotionalism = 49.1 (4.4), non-emotionalism = 48.6 (4.2).

Mean (SD) of MASS Avoidance subscale: (n=11), emotionalism = 22.2 (2.8), non-emotionalism = 25.2 (4.0).

Mean (SD) of MASS Helplessness/hopelessness subscale: (n=11), emotionalism = 20.0 (1.9), non-emotionalism = 21.3 (2.2).

Mean (SD) of MASS Avoidance subscale: (n=11), emotionalism = 1.7 (0.8), non-emotionalism = 1.9 (0.8).

Mean (SD) of MASS Helplessness/hopelessness subscale: (n=11), emotionalism = 10.9 (2.5), non-emotionalism = 14.1 (3.5).

We thank those patients who participated in the study and the staff of local hospitals and the Leeds Stroke Database for their invaluable help. We also thank Dr Louise Dye for her statistical advice. This study was completed as part of work for the degree of DClinPsychol at Leeds University (SE).

STEVEN ECCLES
ALLAN HOUSE
Division of Psychiatry and Behavioural Sciences in Relation to Medicine, University of Leeds, Leeds, UK

PETER KNAPP
Stroke Outcome Study, Research School of Medicine, Leeds, UK

Correspondence to: Dr Allan House, Division of Psychiatry and Behavioural Sciences in Relation to Medicine, University of Leeds, 15 Hyde Terrace, Leeds LS2 9LT, UK.

Paraneoplastic stiff limb syndrome

Stiff man syndrome (SMS) is a rare, severe progressive motor disorder characterised by painful spasms, symmetric axial muscle rigidity, and uncontrollable contractions leading to distorted posturing. The disorder has been associated with the autoantigens, glutamic acid decarboxylase (GAD), and amphiphysin, which are cytoplasmic proteins in neurons of the CNS. A large series of patients with SMS found that most have autoantibodies against GAD, whereas amphiphysin is presumably the predominant autoantigen in paraneoplastic SMS. Recently, Richard et al. presented four patients with a stiff leg syndrome marked by progressive rigidity and spasms of the lower extremities. This group of patients tested negative for anti-GAD antibody but positive for anti-Ri antibodies.

Paraneoplastic stiff limb syndrome refers to the focal form of SMS when one or more distal limbs are involved; two of their patients were also anti-GAD antibody positive, but none were tested for antibodies to amphiphysin or identified as having an underlying neoplasm. We present a patient who clinically conforms to the stiff limb syndrome who was found to have autoimmune body to GAD and breast cancer.

A 68 year old woman presented with a 1 month history of painful spasms in her legs. Cramps were associated with tactile stimuli and emotional upset. Within weeks, inversion began at the left and then right ankle, making ambulation difficult. Her medical history was significant for Graves’ disease treated with thyroxin and radioactive iodine, and hyperlipidaemia. She was a chronic smoker. General examination was noteworthy for lymphadenopathy in the right axilla. Her mental status was worse during periods of lower extremity spasms, during which she became anxious, diaphoretic, and tachycardic. Cranial nerve and motor evaluations were unremarkable, but assessment of the left leg, due to painful spasms elicited by light touch, was difficult. Inversion and plantar flexion were essentially fixed at the left ankle but could be overcome on the right. Deep tendon reflexes were 3+ in the upper and lower extremities, with sustained clonus at the right ankle. Sensory examination revealed the exception of hyperesthesia in the distal lower extremities, and coordination testing were grossly normal. No hyperlordosis or myoclonus was noted. Gait was limited due to ankle posturing.

The laboratory evaluation was noteworthy for a CSF with increased IgG indices (2.5, 3.4; normal, 0.2–0.8) and oligoclonal bands (5, 5) but no pleocytosis. Serological testing for anti-Hu, anti-Yo, and anti-Ri antibodies was unremarkable, and the haemoglobin A1C was 6.6 (5.6–7.7)%. Skin biopsy at three sites on the patient’s leg showed diminished epidermal nerve fibre density and terminal axonal swelling distally, consistent with a small fibre sensory neuropathy. The patient would not tolerate EMG. Magnetic resonance images of the brain and the entire spinal cord were normal. Fine needle aspiration of a soft tissue right axillary mass showed metastatic adenocarcinoma. On an open surgical procedure, infiltrating duct carcinoma of the breast was identified. Anti-GAD antibodies were negative by indirect immunofluorescence, chemical assay and immunoprecipitation, but antibodies to amphiphysin were not detected by immunocytochemistry, immunoprecipitation, or western blotting (Dr P De Camilli, Yale University).

Ongoing therapy with clonazepam and a trial of oral dexamethasone did not improve the lower extremity symptoms. The patient’s ankle posturing continued a slow progression to marked inversion, with spontaneous extension of hallucis longus. The patient died 18 months after symptom onset. Gross necropsy attributed the cause of death to aspiration pneumonia. Neuropathological evaluation showed a grossly normal spinal cord. Microscopically, the lumbar cord had mild reactive gliosis in the anterior horns but no evidence of inflammation. Sections of the frontal cortex, pons, and medulla showed mild diffuse reactive astrogliosis. Stiff man syndrome is increasingly recognised as a heterogeneous disorder. Other case reports have documented patients with “focal” disease involving either lower, upper extremity posturing, or contrast

\[ F = 15.33, p < 0.001 \]


Letters, Correspondence, Book reviews, Correction
with the “diffuse” axial and subsequent proximal muscle distribution of the classic disorder. Our patient differs from those reported with stiff leg syndrome in that an occult malignancy was present. Unfortunately, we were unable to obtain electrophysiological studies for comparison. The search for a paraneoplastic process was based on the findings of axillary lymphadenopathy and an abnormal CSF. Our patient is only the second reported patient with paraneoplastic SMS associated with anti-GAD antibody; the other reported patient with paraneoplastic SMS had upper limb rigidity in the setting of breast cancer associated with anti-GAD antibody; the other reported patient with paraneoplastic SMS had upper limb rigidity in the setting of breast cancer associated with anti-GAD antibody. Our patient is only the second reported patient with paraneoplastic SMS associated with anti-GAD antibody; the other reported patient with paraneoplastic SMS had upper limb rigidity in the setting of breast cancer associated with anti-GAD antibody. Our patient is only the second reported patient with paraneoplastic SMS associated with anti-GAD antibody; the other reported patient with paraneoplastic SMS had upper limb rigidity in the setting of breast cancer associated with anti-GAD antibody.

Paraneoplastic processes can affect any component of the nervous system and, occasionally, multiple levels, as in the syndrome of sensory neuronopathy-encephalomyelitis. Our patient’s findings were not entirely consistent with criteria for classic SMS in that an apparent encephalopathy and a small fibre neuropathy were identified—for example, her dysautonomia (tachycardia and relative hypertension) during spasms may have been a manifestation of involvement of small fibres. The role of autoantibodies in the pathogenesis of SMS and cancer is unclear. Via its probable function in endocytosis, amphiphysin has been postulated to play a part in the regulation of growth factor internalisation; however, the absence of an autoimmune response to this antigen in our patient suggests that other mechanisms of oncogenesis in SMS exist. Given anecdotal evidence of improvement in paraneoplastic SMS after treating the underlying malignancy, we suggest that all patients with SMS, diffuse or focal, be screened for occult cancer.

ISAAC E SILVERMAN
Department of Neurology, Johns Hopkins University, Baltimore, USA

Correspondence to: Dr I E Silverman, Johns Hopkins Hospital, Pathology 509, 600 North Wolfe Street, Baltimore, MD 21287, USA; Telephone 001 410 955 6626; fax 001 410 614 1008; email iisilver@jhmi.edu


Tetrodotoxin intoxication in a uraemic patient

Tetrodotoxin intoxication results from ingesting puffer fish or other animals containing the toxin. Clinical presentation is mainly acute motor weakness and respiratory paralysis. Death is common in the worst affected victims. Although the severity of the symp-toms generally depends on the amount of toxin ingested, it may be influenced by the victim’s medical condition, as described in this report. The patient was a 52 year old uraemic woman. The uraemia was of unde-fined aetiology. Over the past 3 years she has received regular haemodialysis. One day both she and her husband, a healthy 55 year old man, ate a fish soup. About 3 hours after the meal she developed a headache and a lingual and circumoral tingling sensation and numbness at the distal parts of all four limbs. She was dizzy and unsteady, had difficulty in swallowing, and became very weak. She was taken to the emergency service and was placed on machine assisted ventilation as respira-tory distress and cyanosis developed. Her husband remained asymptomatic throughout this time.

The patient’s condition kept on deteriorating, developing eventually into a comatous-like state with no spontaneous or reflexive eye opening or limb movement within 30 min-utes of intubation. On neurological examina-tion, the pupillary light reflex was absent and oculocephalic manoeuvre elicited no ocular movements. All four limbs were areflexic and Babinski’s signs were absent. Brain CT and laboratory studies of arterial blood gas (under assisted ventilation), electrolytes, liver func-tion, blood glucose, and CSF study were unremarkable. An examination of renal function indicated chronic renal insufficiency with mild azotaemia (urea nitrogen 70 mg/dl, creatinine 9.1 mg/dl). An EEG, recorded 18 hours after the onset of symptoms when the neurological condition was unchanged, showed posterior dominant alpha waves intermixing with trains of short duration, diffuse theta waves. When brief noxious stimuli were applied to the sternum, they were replaced transiently by beta activities. The findings suggested that the profound neurological dysfunction might be peripheral in origin. The patient was given a course of haemodialysis according to the set schedule for uraemia at 21 hours after onset of the symptoms. Her condition improved dramati-

Changes in the symptoms of poisoning in relation to each course of haemodialysis. Scales in the vertical axis represent the arbitrary measurements of severity of each symptom; the numbers indicating day(s) after onset; i=6 haemodialysis).
sensory analysis. She could open her eyes and she communicated and answered questions correctly by blinking. Pupillary reflex recovered and voluntary eye movements were limited only at the extreme lateral gaze. Muscle power was grade 3 and 4 in the proximal and distal parts of the lower limbs, respectively. Tendon reflexes were absent. She was taken off mechanical ventilation the next day. Her clinical condition continued to improve and her symptoms subsided in a stepwise pattern, in response to each course of haemodialysis (figure). When recalling, she could remember certain events such as the recording of the EEG, but was “too weak to move” at that time. She regained her initial strength by the time she was discharged on day 16.

When analysing the remains of the cooked fish (identified as *Yeongichthys nebulae*), tetrodotoxin was demonstrated by thin layer chromatography, and cellulose acetate membrane electrophoresis. Toxicity was assayed by using Institute of Cancer Research strain adult male mice and the toxicity score was 25 mouse units (MU)/g in fish muscle (1 MU = 0.016 of the TCR strain mice) (1). Tetrodotoxin exerts its effect through binding with and blocking the voltage dependent sodium channel. The voltage clamp experiments showed that tetrodotoxin diminishes the sodium inward current responsible for the depolarization of excitation membrane. The gating properties of the sodium channel, such as the activation and inactivation mechanism, are not altered—that is, the sodium channel is not permanently damaged and its function recovers when the bound toxin is released. In uraemia, ion conductance through the sodium channel is also impaired. Sodium permeability through excitatory membranes is reduced and small inward sodium current and reduced action potential amplitudes are noted in experimental uraemic neuropathy. By contrast with the effects of tetrodotoxin, uraemia changes the basic property of the sodium channel by an increased inactivation and an impaired activation mechanism. The excitability of peripheral nerves will be more significantly depressed when these two conditions coincide, with the synergistic effect of uraemia and tetrodotoxin is obvious in this incident in which the patient and her husband ingested roughly an equal amount of tetrodotoxin (about 200 μg, calculated as toxic score times the weight of ingested fish).

The amount is about 10% of the estimated lethal dose in humans—2200 μg/60 kg body weight1 (body weights of the patient and her husband were 54.5 and 62 kg, respectively)—and caused no clinical evidence of poisoning in the healthy person. It was of interest that the CNS was relatively spared from the toxicity as the EEG showed a posterior dominant, slowly reactive alpha rhythm and the patient retained consciousness when the symptoms were at their most severe.

One of the most striking clinical features in our patient was the response to haemodialysis. During the small amount of fish ingested, the dramatic improvement of her clinical condition was most likely attributed to the rapid elimination of absorbed toxin in the course of haemodialysis, rather than spontaneous recovery. The physical and chemical properties of tetrodotoxin are also supportive to this hypothesis. It has a low molecular weight (C11H17N3O8), is water soluble, and not significantly bound to protein—all these features are found in toxins amenable to haemodialysis. Traditionally, the management of tetrodotoxin intoxication is mainly supportive, such as gastric lavage to remove unabsorbed toxin and machine assisted ventilation when respiration is severely affected. We suggest that haemodialysis may be an effective method in the treatment of tetrodotoxin intoxication.

**Correspondence to:** Dr Shun-Sheng Chen, Department of Neurology, Kaohsiung Medical College Hospital, 100 Shih-Chung 1st Road, Kaohsiung City 807, Taiwan. Telephone 00886 7 3234237; email sheng@mail.nsysu.edu.tw


**Relation between critical illness polyneuropathy and axonal Guillain-Barré syndrome**

The clinical entity critical illness polyneuropathy occurs almost exclusively in patients in critical care units and has been characterised as a complication of sepsis and multiple organ failure. Critical illness polyneuropathy may be a common cause of the difficulty in weaning patients from the ventilator, particularly those who show intractable ventilator dependence. All the measures used to prevent or prevent severe multiple organ failure are the main methods now used to deal with critical illness polyneuropathy. Knowledge of this type of polyneuropathy is of help in making decisions about respiratory techniques, nursing care, prognosis, and overall management. Moreover, recognition of critical illness polyneuropathy indicates the need for physiotherapy, rehabilitation, and other supportive measures as the patient recovers.

Infection caused by the gram negative bacteria *Campylobacter jejuni*, a leading cause of acute but with subsequent improvement in four limbs, occasional involvement of facial muscles and frequent involvement of the muscles of respiration, the depression or absence of deep tendon reflexes, and some evidence of distal sensory in the EMG laboratory, they found marked differences between the two types of polyneuropathy. Patients with Guillain-Barré syndrome who were studied in their EMG laboratory, they found marked differences between the two types of polyneuropathy. Patients with Guillain-Barré syndrome who were studied in their EMG laboratory, they found marked differences between the two types of polyneuropathy. Patients with Guillain-Barré syndrome who were studied in their laboratory, they found marked differences between the two types of polyneuropathy. Patients with Guillain-Barré syndrome who were studied in their laboratory, they found marked differences between the two types of polyneuropathy. Patients with Guillain-Barré syndrome who were studied in their laboratory, they found marked differences between the two types of polyneuropathy. Patients with Guillain-Barré syndrome who were studied in their laboratory, they found marked differences between the two types of polyneuropathy. Patients with Guillain-Barré syndrome who were studied in their laboratory, they found marked differences between the two types of polyneuropathy. Patients with Guillain-Barré syndrome who were studied in their laboratory, they found marked differences between the two types of polyneuropathy. Patients with Guillain-Barré syndrome who were studied in their laboratory, they found marked differences between the two types of polyneuropathy. Patients...
of acute diarrhoea, commonly precedes the development of Guillain-Barré syndrome.1 There is a close association between axonal Guillain-Barré syndrome and antecedent C jejuni infection.2 The antecedent infectious symptom was diarrhoea in three of five patients with axonal Guillain-Barré syndrome described by Feasby et al.3 Observations by Griffin et al4 confirmed that C jejuni follows C jejuni infection. Serum samples from patients with axonal Guillain-Barré syndrome subsequent to C jejuni enteritis often have a high class autoantibodies to gangliosides GM1, GM1b, GD1a, or GalNAc-GD1a in the acute phase of the illness,5 and there is molecular mimicry between these gangliosides and the lipopolysaccharides of C jejuni isolates from patients with Guillain-Barré syndrome.6 This ganglioside mimicry may trigger high production of the IgG anti-ganglioside antibodies and these autoantibodies may cause motor nerve dysfunction in patients with GBS.

Interestingly, Hagenese et al7 reported a case of “C jejuni bacteremia and subsequent Guillain-Barré syndrome” that occurred in a patient with chronic graft versus host disease and extensive intestinal involvement. Because there was acute flaccid paralysis associated with sepsis, some physicians might have diagnosed critical illness polyneuropathy. Conversely, the existence of this case strongly suggests that some diagnoses of critical illness polyneuropathy should actually be axonal Guillain-Barré syndrome or AMSAN. Our hypothesis of the nosological relation between critical illness polyneuropathy and Guillain-Barré syndrome is shown in the figure. Serum IgG antibodies against GM1, GM1b, GD1a, or Gal NAc-GD1a could be used as immunological markers for axonal Guillain-Barré syndrome.8 To examine the aetiology of critical illness polyneuropathy and its nosological relation to axonal Guillain-Barré syndrome, it is necessary to investigate whether patients with critical illness polyneuropathy have anti-ganglioside antibodies during the acute phase of the illness.

Nobuhiro Yuki
Koichi Hirata
Department of Neuropsychiatry,
Dokkyo University School of Medicine,
Japan

Correspondence to: Dr Nobuhiro Yuki, Department of Neuropsychiatry, Dokkyo University School of Medicine, Kitakobayashi 880, Mibu, Shimotsuga, Tochigi 321-0293, Japan.


Repetitive transcranial magnetic stimulation in the treatment of chronic negative schizophrenia: a pilot study

Recently, a new technology known as repetitive transcranial magnetic stimulation (RTMS) has been developed.1 In 1994, the use of magnetic stimulation in clinical psychiatry was suggested.2 Since then, it has been used in the study or treatment of obsessive-compulsive disorder, conversion disorder, schizophrenia, and particularly, depression.3

Our pilot study aimed to assess the possible adverse effects of this treatment in chronic schizophrenic patients with severe negative symptoms; to evaluate if direct RTMS of the prefrontal cortex might improve negative symptoms or cognitive impairments4 in patients with chronic schizophrenia; and thirdly, to note if RTMS might modify the deficit in prefrontal cortical activity, often related to the hypofrontality established in schizophrenia,5 specially under conditions of task activation.

Six right-handed patients with chronic schizophrenia were identified at the outpatient psychiatric service of the Hospital Clinic of Barcelona. There were two men and four women (mean age 39).

Exclusion criteria included alcohol or substance abuse dependence disorder in the last 5 years, focal neurological or systemic neurological illness, taking cerebral metabolic activator or vasodilator medications, electroconvulsive therapy within 6 months, and significant abnormal findings on laboratory examination.

All patients were taking neuroleptic drugs, but a stable dose for at least 3 months was required. All patients were studied off benzodiazepines for at least 1 week before beginning the treatment. During the RTMS, psychotropic medications were continued at the initial dosage.

All patients were admitted to hospital. Inpatients underwent the UKU side effects scale,6 the positive and negative syndrome scale (PANSS), and a neuropsychological battery, the day before beginning the treatment and at the end of the treatment. The UKU scale was also administered after each session.

An equivalent neuropsychological battery was used on both occasions, which consisted of the block design subtest of the Wechsler memory scale, the day before beginning the treatment and at the end of the treatment. The UKU scale was also administered after each session.

A brain SPECT study was performed using a rotating dual head gamma camera, fitted with high resolution fanbeam collimators. Two trans-Tc-HMPAO SPECT scans with diagnostic accuracy were obtained, such as the Wisconsin card sorting test (WCST), were performed on each patient (24 hours before the beginning of the treatment and 24 hours after the last session).

RTMS was given with a Mag Pro magnetic stimulator, 5 days a week, during 2 weeks, at a dosage of 20 Hz for 2 seconds, once per day. The motor threshold was determined by visualisation of finger movement. A butterfly magnetic coil was placed tangential to the orbital area, on the C3 and C4 EEG point. The motor threshold was determined by visualisation of finger movement. The remainder of the patients tolerated the RTMS well, with minimal side effects (mild headache and tinnitus).

Critical SPECT of one patient was reported to be normal, showing no evidence of hypofrontality. The remainder of the patients showed hypofrontality on the initial re-imaging. The results after RTMS indicated no change in the hypofrontality.

Negative symptoms showed a general decrease for all patients (table). Significance (p<0.02) was noted on the PANSS negative symptoms subscale. These patients seemed to be more sociable than when originally seen. Nevertheless, clinical effects of the RTMS were subtle and difficult to distinguish from those derived from the supportive environment of the psychiatric ward.

With regard to the neuropsychological battery, we found a general improvement in all post-treatment scores (table), but only delayed visual memory achieved significance (p<0.05). This feature might be basically explained by improvement of attention, specifically of the maintenance of attention, which allows the correct function of the working memory. There are still ethical and methodological limitations regarding the power of our conclusions, it is certain that there has been an improvement in the attentional capability.

We found that all patients (except one, who was always within the normal range) diminished their number of perseverative answers, and errors on WCST (items characteristically altered in schizophrenia) after the RTMS. However, significance was not achieved on any WCST scores.

Two patients who initially did not perform any categories on WCST, after the treatment, achieved one category, a possible indication of improvement of the working memory. This change leads us to consider a research strategy previously reported, in which the WCST is used as a screening test for selecting schizophrenic patients. These patients achieving low category scores would be compared to higher category scorers in an effort to identify a subgroup most likely to benefit from RTMS.

Taking into account these mild improvements together, and the lack of changes in

<table>
<thead>
<tr>
<th>Test</th>
<th>Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Block design</td>
<td>49 (11.95) NS</td>
</tr>
<tr>
<td>Trail making test A</td>
<td>38.9 (14.1) NS</td>
</tr>
<tr>
<td>Trail making test B</td>
<td>38.3 (4.5) NS</td>
</tr>
<tr>
<td>Immediate visual reproduction</td>
<td>41 (10.03) NS</td>
</tr>
<tr>
<td>Delayed visual reproduction</td>
<td>54.8 (11.2) NS</td>
</tr>
<tr>
<td>Immediate verbal paired associates</td>
<td>46.18 (2.3) p&lt;0.05</td>
</tr>
<tr>
<td>Delayed verbal paired associates</td>
<td>53.8 (14.6)</td>
</tr>
<tr>
<td>PANSS-NG</td>
<td>54 (7.46) NS</td>
</tr>
<tr>
<td>PANSS-N</td>
<td>59.5 (10.03) NS</td>
</tr>
<tr>
<td>PANSS-P</td>
<td>8.8 (1.1) NS</td>
</tr>
</tbody>
</table>

Pre=pretreatment; Post=post-treatment; PANSS=positive and negative syndrome scale; PG=general psychosis scale; NG=negative scale; P=positive scale.


Sensory alien hand syndrome

The case report by Ay et al of alien hand syndrome and review of the literature neglected the intriguing issue of why in every case so far reported the patient seems to be terrified of the alien limb. Not believing that you are any more in control of a limb is not likely to be a pleasant experience.

Those with alien hand syndrome seem to jump to extremely negative conclusions concerning the intent of the limb. Typically, in the report of Ay et al at least, the common belief is that the limb has deeply malevolent intentions towards the victim.

It is this aspect of alien hand syndrome that I suggest also needs incorporating into its neurophysiological explanations, and which provides a clue as to why our everyday experience of being in charge of our bodies, and so initiating all personal action, itself has a neurological basis. In other words, while the brain is the seat of conscious and experiential processes, there is also a part of our nervous system which is responsible for our belief that we have free will over our behaviour. Patients with alien hand syndrome think that they are no longer in control of a limb because the part of the brain that gives us the sensation of control over our bodies has been damaged. When that happens, our limbs seem to act independently of us.

Research conducted in the 1980s has found that the same electrical brain wave changes that characteristically preclude all limb movements, occur several 100 ms before we seem to consciously decide to move a limb. If our conscious decision to act is preceded by brain changes that anticipate action, then our “decision” to choose how to behave or “freedom”, as in the term free will, is in fact illusory. Our choices have in a sense been decided beforehand by our brains.

Spence argues that evidence such as this, combined with phenomena such as alien hand syndrome, means that philosophers have to reconsider whether we have free will. He argues that these data suggest that our sense of agency is illusory and it follows that most of us share in common the useful delusion that we have free will. Patients with alien hand syndrome have lost this experience in relation to a particular limb. There is a sense then that those who experience the syndrome are closer to the reality of how much we are responsible for our actions than the rest of us. This is because the function of the part of the brain that normally functions to make us think that we have conscious freedom of will. They develop the experience, therefore, of becoming mere remote spectators to the actions of their bodies.

Defenders of human “free will” argue what happens before the brain itself decides to act is still unknown, and there may be a role for our own autonomy there. But even these free will guardians concede the neurological research indicates that whatever happens before the brain is roused, must occur below our conscious awareness.

Yet in alien hand syndrome the patient thinks that the hand has hostile motivations: it is invariably the case that the patient not only thinks that the limb is “not self” but finds that the limb behaves towards the self in a destructive and aggressive manner. This could be explained by the activation of emotions and so initiating all personal action, itself has a neurological basis. In other words, while the brain is the seat of conscious and experiential processes, there is also a part of our nervous system which is responsible for our belief that we have free will over our behaviour. Patients with alien hand syndrome think that they are no longer in control of a limb because the part of the brain that gives us the sensation of control over our bodies has been damaged. When that happens, our limbs seem to act independently of us.

Research conducted in the 1980s has found that the same electrical brain wave changes that characteristically preclude all limb movements, occur several 100 ms before we seem to consciously decide to move a limb. If our conscious decision to act is preceded by brain changes that anticipate action, then our “decision” to choose how to behave or “freedom”, as in the term free will, is in fact illusory. Our choices have in a sense been decided beforehand by our brains.

Spence argues that evidence such as this, combined with phenomena such as alien hand syndrome, means that philosophers have to reconsider whether we have free will. He argues that these data suggest that our sense of agency is illusory and it follows that most of us share in common the useful delusion that we have free will. Patients with alien hand syndrome have lost this experience in relation to a particular limb. There is a sense then that those who experience the syndrome are closer to the reality of how much we are responsible for our actions than the rest of us. This is because the function of the part of the brain that normally functions to make us think that we have conscious freedom of will. They develop the experience, therefore, of becoming mere remote spectators to the actions of their bodies.

Defenders of human “free will” argue what happens before the brain itself decides to act is still unknown, and there may be a role for our own autonomy there. But even these free will guardians concede the neurological research indicates that whatever happens before the brain is roused, must occur below our conscious awareness.

Yet in alien hand syndrome the patient thinks that the hand has hostile motivations: it is invariably the case that the patient not only thinks that the limb is “not self” but finds that the limb behaves towards the self in a destructive and aggressive manner. This could be explained by the activation of emotions and so initiating all personal action, itself has a neurological basis. In other words, while the brain is the seat of conscious and experiential processes, there is also a part of our nervous system which is responsible for our belief that we have free will over our bodies, our minds... decide that if ourselves are not in control then someone or something else must be. We would offer that the value of our particular case is that it was due to a central dea... therefore the term “sensory alien hand syndrome”. As...
opposed to the idea that “we know our limbs belong to us because they obey us,” we know that our limbs belong to us because they provide us with sensory input that is recognised as self. Many patients with movement disorders or paralysis lose control of their limbs but still have no difficulty in realising them as self. Indeed even in “phantom limb” there is sense of self due to central processes in the absence of a limb. Our patient, as do others with amnesia and primary abnormalities of central sensory systems, shows perhaps that it is central sensory processes that are the key to identifying “self”. We know our limbs not because they obey us but because of a pattern of sensory innervation that accompanies our own limb movements. When this pattern never reaches specific cortical regions, then the limb is not perceived as self, called “amorphosynthesis” by De Renzi and Berti. Selective deafferentation by the centrally deafferented limb in “sensory” or “posterior” alien hand syndrome, or kinaesthetic stimuli due to movement of the limb as in the “anterior” or “motor” alien hand syndrome, is perceived as due to another person or thing without critical questioning. This raises the most interesting question of what brain region is deafferented in the anterior alien hand syndrome where somatic sensory processing is intact.

It is not our clinical experience nor the conclusions based on published reports that all patients suffering with alien hand syndrome are teriffied by the affected limb. In one author’s experience (BHP), two patients with alien hand syndrome and related intermanual conflict were irritated by but not terrified by their opposing limbs simultaneously. The more critical issue is whether the patient was amused but rather indifferent to his affected left side. The most terrifying situation we have heard is when the patient identified his affected left side as belonging to his mother in law. A patient reported by Heilman’s group entertained only the limbs, and his a

Vasomotor reactivity is exhausted in transient ischaemic attacks with limb shaking

The article of Baumgartner and Baumgartner entitled “Vasomotor reactivity is exhausted in transient ischaemic attacks with limb shaking” provides interesting new information regarding patients with involuntary limb movements contralateral to haemodynamic failure from severe carotid artery occlusive disease. The authors evoke an “exhausted cerebral vasoreactivity in the hemispheres opposite the involuntary limb movements”. In their report, involuntary movements affected only the limbs, and displayed no tonic contraction, tonic-clonic jerking, or Jacksonian march and no epileptic activity during attacks. These findings led the authors to strongly argue against seizures as the cause of limb shaking in these transient ischaemic events.

In contradistinction, a 72 year old right handed man was admitted to our hospital with a 3 month history of episodic weakness and numbness of the right arm. The patient then had six discrete stereotypic episodes of right arm weakness and clumsiness that were also associated with arterial bruit in speaking. Several episodes of dysarthria, numbness and weakness of the right arm and leg (MRC grade 4/5) were seen, unrelated to posture, some of which occurred when the patient was supine. Most episodes were characterised by slight tremulousness and asterixis-like movements of the outstretched right arm. There was a return to baseline functioning between events. Video/EEG monitoring, however, showed low voltage spikes in the left central-parietal head regions contralateral to the facial twitching and the right arm and right leg weakness. Although ongoing clinical and EEG seizures activity stopped after 2 mg intravenous lorazepam, they reoccurred after loading with phenytoin. Because angiography disclosed a greater than 95% stenosis of the left internal carotid artery (while the patient was treated with phenytoin at a concentration of 16.5 mg/L), the patient was anticoagulated with heparin, but episodes continued. It was only after a left carotid endarterectomy that all episodes ceased, tremulousness, and EEG epileptiform activity stopped. They did not recur over the past 5 years.

The literature includes several cases of focal motor inhibitory seizures causing weakness. Although it is impossible to prove a negative, it could be argued that although no epileptiform or other evidence of seizure activity is present in a particular case, the abolition of ongoing clinical and EEG evidence of inhibitory motor activity by intravenous diazepam argues in favour, at least in part, of a cortical contribution. The fact that in virtually all reported cases, abnormal movements are more definitively resolved by carotid endarterectomy suggests for an underlying ischaemic aetiology that induces focal seizures. There are few reports that clearly delineate the interaction and association of inhibitory focal motor seizures and transient ischaemic attacks, as there are few sequential trials of antiseizure drugs or anticoagulation (under EEG monitoring) and finally carotid endarterectomy. Several authors support the concept of an inhibition of motor function in parietal and secondary somatosensory re


Vasomotor reactivity is exhausted in transient ischaemic attacks with limb shaking

The article of Baumgartner and Baumgartner entitled “Vasomotor reactivity is exhausted in transient ischaemic attacks with limb shaking” provides interesting new information regarding patients with involuntary limb movements contralateral to haemodynamic failure from severe carotid artery occlusive disease. The authors evoke an “exhausted cerebral vasoreactivity in the hemispheres opposite the involuntary limb movements”. In their report, involuntary movements affected only the limbs, and displayed no tonic contraction, tonic-clonic jerking, or Jacksonian march and no epileptic activity during attacks. These findings led the authors to strongly argue against seizures as the cause of limb shaking in these transient ischaemic events.

In contradistinction, a 72 year old right handed man was admitted to our hospital with a 3 month history of episodic weakness and numbness of the right arm. The patient then had six discrete stereotypic episodes of right arm weakness and clumsiness that were also associated with arterial bruit in speaking. Several episodes of dysarthria, numbness and weakness of the right arm and leg (MRC grade 4/5) were seen, unrelated to posture, some of which occurred when the patient was supine. Most episodes were characterised by slight tremulousness and asterixis-like movements of the outstretched right arm. There was a return to baseline functioning between events. Video/EEG monitoring, however, showed low voltage spikes in the left central-parietal head regions contralateral to the facial twitching and the right arm and right leg weakness. Although ongoing clinical and EEG seizures activity stopped after 2 mg intravenous lorazepam, they reoccurred after loading with phenytoin. Because angiography disclosed a greater than 95% stenosis of the left internal carotid artery (while the patient was treated with phenytoin at a concentration of 16.5 mg/L), the patient was anticoagulated with heparin, but episodes continued. It was only after a left carotid endarterectomy that all episodes ceased, tremulousness, and EEG epileptiform activity stopped. They did not recur over the past 5 years.

The literature includes several cases of focal motor inhibitory seizures causing weakness. Although it is impossible to prove a negative, it could be argued that although no epileptiform or other evidence of seizure activity is present in a particular case, the abolition of ongoing clinical and EEG evidence of inhibitory motor activity by intravenous diazepam argues in favour, at least in part, of a cortical contribution. The fact that in virtually all reported cases, abnormal movements are more definitively resolved by carotid endarterectomy suggests for an underlying ischaemic aetiology that induces focal seizures. There are few reports that clearly delineate the interaction and association of inhibitory focal motor seizures and transient ischaemic attacks, as there are few sequential trials of antiseizure drugs or anticoagulation (under EEG monitoring) and finally carotid endarterectomy. Several authors support the concept of an inhibition of motor function in parietal and secondary somatosensory re

PETER W KAPLAN
John Hopkins Bayvsters Medical Center, 4940 Eastern Avenue, Baltimore, MD 21224, USA

Baumgartner and Baumgartner reply:
We are grateful for the response of Kaplan to our short report. We agree that somatic inhibitory seizures may mimick transient ischaemic attacks (TIAs). Such TIAs are associated with negative symptoms such as sensorimotor deficits and difficulty with speaking, EEG evidence of seizure activity, and ceasing of the TIAs after the administration of an anticonvulsant drug. Limb shaking TIAs, however, differ in that they are resistant to inhibitory seizures in several ways. (1) They are associated with positive phenomena (limb shaking), and the involuntary movements do not affect the facial musculature. (2) Patients with attacks of shaking movements of the limbs have no EEG evidence of epileptic activity, and involuntary movements do not stop after administration of anticonvulsive therapy. (3) Although the patient presented by Kaplan had a 95% stenosis of the left internal carotid artery, it is unclear whether haemodynamic failure was present or not, because no studies evaluating the haemodynamic reserve of the homolateral hemisphere were presented. This is in accordance with the finding that the involuntary movements as well as the sensorimotor deficits of Kaplans’ patient were not related to atheroma. (4) The pathophysiological mechanisms may be due to disinhibition of subcortical control mechanisms as a result of ischaemia.

In our opinion, it is not clear whether the asterixis-like movements of the outstretched right arm of Kaplan’s patient are due to epileptic seizures, because unilateral asterixis of the outstretched arm has been reported with contralateral vascular lesions affecting almost all cerebral structures except the homolateral hemisphere.

RALF W BAUMGARTNER
Department of Neurology, University Hospital of Bern, Switzerland

IRIS BAUMGARTNER
Division of Angiology, University Hospital of Zürich, Switzerland


Letters, Correspondence, Book reviews, Correction

Department of Neurology, McLean Hospital, 115 Mill Street, Belmont, MA 02178, USA


BOOK REVIEWS


To the MRCP candidate neurology is one of the more daunting specialties. The unfamiliar nerve conduction study and the frankly mysterious EEG can distress an otherwise well rounded senior house officer. Despite the fact that much of neurology is commonly seen on a general medical ward—strokes, dementias and so forth—the general perception is of an unimaginable list of eponymous syndromes and obscure signs. Rather than dwell on the last, in this book Dr Smith tries to address the commoner complaints as examination style questions each with a “simple clinical les-
son”. The “grey case” section, for instance, includes questions on multiple sclerosis, cluster headache, and HSV encephalitis, while broadening the topics to include postinfective demyelination, chronic hemi-


This book, after a short introduction to some of the fundamental features of the disease goes on to provide some 117 illustrations of aspects of the disease from Cruevher’s plates to histopathological specimens and also a heavy leaning to imaging particularly magnetic resonance scanning, as might be expected. There is no doubting the aesthetic impact of this short book. In addition, the fact that these illustrations emanate from a well established figure in the multiple sclerosis world and are likely to be a representative set of personal teaching slides from a successful academic career all vouch for the provenance and informative nature of the atlas. However the place of such a book within a neurologist’s library has to be questioned. There are a plethora of high quality textbooks devoted to all aspects of multiple sclerosis, all well illus-
trated and most in colour. They provide in depth analysis of all aspects of the disease and although their illustrations tend to be smaller this is where I would choose to put my money. It may be that the circulation of this book will be higher than expected as it is likely to be a popular choice for some pharmaceutical companies.

NEIL ROBERTSON


This monograph is the latest to be produced by the American Association of Neurological Surgeons as part of Neurosurgical Topics series. It begins by tracing the history of cal-
varial reconstruction from ancient times. There follows a discussion of the different autologous donor sites and synthetic materi-
als currently available. There is a discussion of calvarial and facial defects. The merits, disadvantages, and contraindications of each are considered. Dural substitutes are then dealt with in simi-
lar fashion. Specific problems, such as scalp reconstruction, the management of commi-
-

cal cerebral arteries. There are increas-
ingly available for the non-invasive imaging of intracranial structures, parti-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

This is the second time that I have been asked to review a book on this topic. The first time I approached the task with some scepticism—were neurological diseases in women really so different from those in men that they warranted own text book? But I rapidly became a convert to the cause, being reminded that there are issues specific to females that influence both disease, investigation, and treatment (pregnancy, breast feeding, menopause, to name the most obvious) and that not all neurological diseases attack the sexes equally. There are also wider socio-economic and legal issues that play a part in the complete disease picture which many of us neglect too often but which this book is careful to address (see below). Leaving content aside for a moment, this is a beautifully presented book; clearly headed and with wide use of well constructed tables. It encourages one to read on. It seems up to date and well referenced.

The contributors (40 in total) are exclusively American, and east coast American at that with only occasional forays westward. The text is divided into three sections. The first, entitled General Disease in Women includes an anatomical chapter considering the sex differences of regional brain structure and function. More novel for this type of text, it contains two thoughtful chapters considering women's health and its relation to neurological disease representing these diseases with emphasis on their e

CORRECTION


During the editorial process the descriptions of the histograms in figure 4 (p 614) were wrongly ascribed. The corrected figure is reproduced below.

Figure 4 Correlation of clinical response (grade 0 or 1 response indicates non-responders, grade 2 response indicates reduced response, and grade 3 or 4 are responders) with response to test injections.